Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study

Abstract

Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (N = 14,524) had a higher risk for hyperlipidemia than the control group (N = 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD.

Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease

“…Dyslipidemia, characterized by elevated levels of low-density lipoprotein (LDL) cholesterol and triglycerides, poses an increased risk of atherosclerosis and cardiovascular events. Patients with IBD are particularly susceptible to dyslipidemia due to chronic inflammation and malnutrition [60]. Weight fluctuations are common among individuals with IBD, resulting from disease activity, medication side effects, or dietary changes.…”

Evaluation of Lipid Profile Changes In Patients With Inflammatory Bowel Disease: A Single Center Experience

“…Firstly, the chronic inflammatory milieu characteristic of IBD has the potential to disrupt lipid metabolism through various mechanisms, including the release of proinflammatory cytokines, alterations in gut microbiota, and changes in dietary habits [9]. Secondly, the presence of dyslipidemia in IBD patients may have profound implications for their overall health and quality of life, considering the already complex nature of managing this chronic inflammatory condition [10]. Lastly, understanding the dynamics of lipid profiles in IBD patients at a single-center level can offer valuable insights into potential therapeutic targets and strategies to mitigate cardiovascular risk [11].…”